THE VALUE OF P53 AND KI67 AS MARKERS FOR TUMOR PROGRESSION IN THE BARRETTS DYSPLASIA-CARCINOMA SEQUENCE

被引：74

作者：

POLKOWSKI, W

VANLANSCHOT, JJB

TENKATE, FJW

BAAK, JPA

TYTGAT, GNJ

OBERTOP, H

VOORN, WJ

OFFERHAUS, GJA

机构：

[1] Department of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam

[2] Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam

[3] Department of Gastroenterology, Academic Medical Center, University of Amsterdam, Amsterdam

[4] Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, Amsterdam

[5] Department of Pathology, Free University Hospital, Amsterdam

来源：

SURGICAL ONCOLOGY-OXFORD | 1995年 / 4卷 / 03期

关键词：

BARRETT; CARCINOMA; DYSPLASIA; KI67; ANTIBODY; P53; GENE;

D O I：

10.1016/S0960-7404(10)80021-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the Barrett's oesophagus (BE) progression from metaplasia, via dysplasia, into invasive cancer, an aberrant cell proliferation governed by genetic change plays a central role. Alterations of the p53 tumour-suppressor gene appear especially critical and, like the proliferation marker Ki67, can be detected by immunohistochemistry. The purpose of this study therefore was to investigate the clinical value of p53 and Ki67 as markers for tumour progression in BE, and at the same time test the validity of the concept of a metaplasia-dysplasia-carcinoma sequence in BE by correlating the expression of these markers with various grades of dysplasia. Thirty-two lesions (seven negative for dysplasia, five indefinite for dysplasia, 11 low-grade dysplasia and nine high-grade dysplasia) from 25 archival resection specimens were selected for study. Increasing grades of dysplasia showed increasingly p53 accumulation; p53 accumulation was never observed in mucosa without dysplasia. The increasing p53 expression was accompanied by an increased Ki67-labelling index and an upward shift of the proliferative compartment. The results lend support to the multistep progression model of a metaplasia-dysplasia-carcinoma sequence in BE. Expression of p53 and Ki67, markers which can be easily applied on archival material, can be valuable adjuncts for the histopathological diagnosis of dysplasia and may have predictive value for cancer risk.

引用

页码：163 / 171

页数：9

共 37 条

[1]

Spechler SJ, Goyal RK, Barrett's esophagus, N Engl J Med, 315, pp. 362-371, (1986)

[2]

Hamilton SR, Adenocarcinoma in Barrett's oesophagus, Gastrointestinal and Oesophageal Pathology, pp. 683-700, (1989)

[3]

Hameeteman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG, Barrett's esophagus: development of dysplasia and adenocarcinoma, Gastroenterology, 96, pp. 1249-1256, (1989)

[4]

Riddel RH, Goldman H, Ransohoff DF, Et al., Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications, Human Pathology, 14, pp. 931-968, (1983)

[5]

Schmidt HG, Riddell RH, Walther B, Skinner DB, Riemann JF, Dysplasia in Barrett's esophagus, J Cancer Res Clin Oncol, 110, pp. 145-152, (1985)

[6]

Miros M, Kerlin P, Walker N, Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus, Gut, 32, pp. 1441-1446, (1991)

[7]

Pera M, Trastek VF, Carpenter HA, Allen MS, Deschamps C, Pairolero PC, Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy?, Ann Thorac Surg, 54, pp. 199-204, (1992)

[8]

Altorki NK, Sunagawa M, Little AG, Skinner DB, High-grade dysplasia in columnar-lined esophagus, Am J Surg, 161, pp. 97-100, (1991)

[9]

Rice TW, Falk GW, Achkar E, Petras RE, Surgical management of high-grade dysplasia in Barrett's esophagus, Am J Gastroenterol, 88, pp. 1832-1836, (1993)

[10]

lascone C, DeMeester TR, Little AG, Skinner DB, Barrett's esophagus: functional assessment, proposed pathogenesis and surgical therapy, Arch Surg, 118, pp. 543-549, (1983)

← 1 2 3 4 →